Contraceptive spray touted as safer alternative to pills, patches
A new contraceptive spray currently in clinical trials is showing positive results in patients, according to Australian drug maker Acrux. The company’s Nestorone MDTS is a fourth-generation progestin contraceptive that has no androgenic hormonal effects and a good safety profile. The spray is a small, hand-held, easy-to-use spray designed to provide an easy and convenient means to deliver a preset dose of therapeutic drug directly to the skin. It is being touted by its maker as a “better choice” for women using hormonal contraceptive pills or patches.